Expert Consensus on Influenza Vaccine and Pneumococcal Vaccination in Elderly People With Chronic Respiratory Diseases (2024) Authors: Lijing Wang, Qiao Yu, Qiong Chen, Pulin Yu, Yunhua Bai, Yunhua Bai, Yufeng Du, Luzhao Feng, Lidong Gao, Lingyun Gao, Baimei He, Junguang Jiang, Wenjing Jiang, Yayun Nan, Zhibin Peng, Yun Peng, Zhujun Shao, Jin Tan, Yingxuan Tian, Bingxiang Wang, Yuhong Wang, Wei Wu, Jianqin Wu, Xiuping Wu, Meizhe Xin, Wei Xiong, Guogang Zhang, Qiang Zhang, Xiangyu Zhang, Zhimian Zhang, Xiongwen Zhou Published: 2026 ABSTRACT ABSTRACTChronic respiratory diseases pose a serious threat to the health of the population due to their high incidence, high disability rate, and poor prognosis. It is necessary to improve the prevention and treatment status of chronic respiratory diseases. Vaccination against influenza and pneumococcal infections can reduce the risk of respiratory infections, lower hospitalization and mortality rates, and alleviate disease burden in individuals with chronic respiratory diseases. However, insufficient public awareness of influenza and pneumococcal vaccines and the lack of recommendation by medical personnel have led to the low actual vaccination rate of influenza and pneumococcal vaccines in elderly people with chronic respiratory diseases in China. Based on existing research evidence both domestically and internationally, this consensus describes the burden of influenza and pneumococcal diseases in elderly people with chronic respiratory diseases, the protective effect and safety of influenza and pneumococcal vaccines, and vaccination recommendations, aiming to promote the vaccination rate of elderly people with chronic respiratory diseases, better play the role of vaccines in preventing influenza and pneumococcal diseases, and reduce the occurrence of respiratory infections and related serious complications in the population with chronic respiratory diseases. Introduction Chronic respiratory diseases (CRD) encompass a spectrum of pulmonary and airway disorders, predominantly featuring chronic obstructive pulmonary disease (COPD), bronchial asthma (commonly referred to as asthma), bronchiectasis, and primary bronchogenic carcinoma (lung cancer). These prevalent chronic conditions among the elderly are characterized by high prevalence, disability, and mortality rates, along with substantial disease burden, ranking as the third leading cause of death globally [1, 2, 3]. From 1990 to 2019, global CRD cases and mortality surged by 39.8% and 28.5%, respectively, culminating in 454.6 million affected individuals and approximately 4 million deaths in 2019. The mortality exhibits a proportional increase with advancing age, positioning CRD as a critical health challenge for aging populations in the context of global demographic aging [1, 4, 5]. Influenza and pneumonia serve as key triggers for CRD exacerbations and poor clinical outcomes. The elderly CRD population demonstrates heightened vulnerability to these infections. Vaccination against influenza and pneumococcal diseases has been shown to mitigate respiratory infection risks, reduce hospitalization rates, and lower mortality [6, 7]. Presently, China's elderly CRD population demonstrates suboptimal vaccination rates for both influenza and pneumococcal vaccines. Substantial attention has been directed toward understanding the necessity, efficacy, safety protocols, and optimal administration strategies of these vaccinations. This consensus integrates extant domestic and international research evidence to formulate expert recommendations regarding influenza and pneumococcal vaccination for China's elderly CRD population. The primary objectives are to standardize vaccination protocols among medical personnel and to promote scientific literacy regarding these vaccinations within the elderly CRD community. The consensus development process and methodology are outlined as follows: (1) Registration: This consensus is formally registered on the International Practice Guideline Registry and Transparency Platform (www.guidelines‐registry.cn), under the registration number PREPARE‐2024CN010. (2) Users and target population: This consensus is designated for use by medical personnel affiliated with the Chinese Center for Disease Control and Prevention (CDC), vaccination departments, geriatric medicine departments, and pulmonary and critical care medicine (PCCM) divisions. The target population comprises elderly individuals suffering from CRD. (3) Objective: To advocate for the administration of influenza and pneumococcal vaccines within the elderly population with CRD, underscoring the critical role of vaccines in mitigating and managing influenza and pneumococcal diseases. The CRD considerations within this consensus chiefly encompass conditions such as COPD, asthma, bronchiectasis, and lung cancer. (4) The expert group: Academically guided by the Geratology Society, Chinese Medical Association, the expert committee comprises specialists from the National Center of Geratology, geriatric department, PCCM, vaccination department, and Chinese CDC. (5) Literature search strategy: Searches were conducted within databases such as Medline, PubMed, CNKI, and the Wanfang Data Knowledge Service Platform. The English and Chinese search terms were [(influenza vaccine) OR (pneumococcus vaccine)] AND [(COPD) OR (asthma) OR (bronchiectasis) OR (lung cancer)]. The timeframe for publication consideration was unrestricted until July 2024. The drafting of the consensus began in October 2023, with the document undergoing discussions and revisions through four rounds of meetings, both online and offline, conducted by the expert committee. Following multiple deliberations, the final version of the consensus was solidified in July 2024. (6) Consensus update: The expert group intends to update this consensus within approximately 3 years, following the international update procedures. The Interrelation Between CRD, Influenza Virus and Pneumococcal Infections Due to the attenuation of systemic and respiratory tract localized immune responses, coupled with factors such as diminished respiratory muscle strength, reduced lung tissue elasticity, and weakened cough reflex, elderly individuals burdened with CRD display a heightened susceptibility to influenza virus and pneumococcal infections. The rate of hospitalization attributable to influenza within the CRD population (30.4%) markedly surpasses that of non‐influenza cases (20.3%), with approximately 80% of influenza‐related excess respiratory mortality transpiring among individuals aged 60 and above. The influenza‐associated excess respiratory disease mortality rate (38.5/100,000) in the elderly significantly eclipses the rate observed in individuals younger than 60 years old (1.5/100,000) [8, 9]. The prevalence of pneumococcal pneumonia among CRD patients is conspicuously elevated compared to those devoid of CRD. Within this demographic, individuals aged 65 and above exhibit a pneumococcal pneumonia incidence 2.7 times greater than those aged 50–64 and 7.7 times that of a non‐CRD group [10]. COPD stands as the most ubiquitous CRD affecting the elderly, serving as a principal cause of mortality. China is home to approximately 100 million COPD sufferers, with prevalence intensifying sharply among the elderly (21.2% in the 60–69 age bracket and 35.5% among those 70 and older). Approximately 1 million people succumb to COPD in China per year, making it the third leading cause of death after ischemic heart disease and stroke [11, 12, 13, 14]. Respiratory infection‐induced acute exacerbations prominently drive fatalities and disease progression in COPD sufferers. A study involving 890,000 adults revealed that influenza‐related hospitalizations in COPD patients aged 65 and above are notably higher than in their non‐COPD peers [15]. A US cohort study further revealed that the annual incidence of community‐acquired pneumonia (CAP) among COPD patients is 9369 per 100,000, substantially exceeding that of non‐COPD counterparts (509 per 100,000). The incidence of CAP in COPD patients increased progressively with age, reaching 20,817 per 100,000 in the COPD population aged 65 and older, with 40 to 64‐year‐olds experiencing a rate of 4824 per 100,000 [16]. The prevalence of asthma among the elderly is increasing yearly. Asthma surveillance data released by the US CDC indicates an increase in asthma prevalence among individuals aged 65 and above, from 7.4% in 2018 to 7.8% in 2020 [17, 18]. The results of the China Pulmonary Health Study indicate that the asthma prevalence rate is 6.0% for those aged 60 to 69 and 7.4% for those aged 70 and older [19]. Furthermore, elderly asthma patients exhibit elevated rates of mortality and hospitalization [20]. A China national survey assessing the severity of acute asthma exacerbations in hospitalized elderly patients discloses that mild cases constitute a mere 7.7%, contrasted with 80.8% for moderate‐to‐severe cases, while critical cases account for 11.5% [21]. Respiratory infections serve as the predominant cause for emergency department visits and hospitalization among elderly asthmatics [22]. The hospitalization rate for influenza‐related severe acute respiratory infections is notably higher in individuals aged 65 and above compared to those between 40 and 64 years of age. A large‐scale study conducted in Germany indicates that adult asthma is a risk factor for pneumococcal infections [23]. Individuals aged 65 and older with asthma exhibit an incidence of pneumococcal pneumonia 3.2 times higher than their counterparts aged 50–64, and 5.9 times that of those without asthma [10]. The prevalence of bronchiectasis increases with age, and the disease burden continues to rise. In China, the prevalence of bronchiectasis among elderly individuals aged 60–69 rose from 134.4 per 100,000 in 2013 to 308.8 per 100,000 by 2017. Similarly, the rates escalated from 217.5 to 500.4 per 100,000 for those aged 70–79, and surged from 242.1 to 588.8 per 100,000 in the octogenarian population. The annual per capita total health expenditure for bronchiectasis patients increased by approximately 2.18 times, while average hospitalization costs rose by roughly 1.83 times [24]. Upper respiratory tract infections pose significant risks for bronchiectasis exacerbations, directly influencing the disease trajectory and prognosis [25]. A study investigating 865 bronchiectasis patients afflicted with influenza, primarily among the elderly, found that 62% of bronchiectasis patients infected with influenza necessitated hospitalization, with 22% experiencing severe illness and respiratory failure during their stay [26]. In adults with pneumonia complicated by bronchiectasis, pneumococci were detected in 30.6% of clinical samples, compared to only 8.1% in those without bronchiectasis [27]. CAP patients with concurrent bronchiectasis exhibited significantly older age and longer hospitalization duration compared to those without bronchiectasis [28, 29]. Lung cancer stands as the leading solid malignancy in terms of incidence and mortality rates. National mortality surveillance data affirms its position as the predominant cancer affecting the elderly [30]. From 2020 to 2050, lung cancer is projected to impose the highest economic cost globally among all cancers [31]. However, lung cancer mortality rates have shown a progressive annual decline [32, 33]. Advances in therapeutic methods have significantly ameliorated lung cancer prognosis, enabling patients to manage the disease chronically through sustained medication. Research indicates that influenza virus infections elevate the mortality risk associated with lung cancer, with the risk among patients aged 65 and older estimated at 14.94 per 100,000 [34]. A retrospective investigation in Canada regarding pneumococcal infections in patients with solid tumors reveals that lung cancer patients (average age of 64) have a 13.4 times higher risk of developing invasive pneumococcal disease compared to normal adults [35]. Current Status of Influenza and Pneumococcal Vaccinations Among the Elderly With CRD Vaccination is an effective measure to prevent influenza virus and pneumococcal infections, subsequently minimizing adverse outcomes. However, the implementation rate of influenza and pneumococcal vaccinations remains distressingly low within China's elderly population suffering from CRD. Statistics illustrate that from 2014 to 2015, the influenza vaccination rate of the elderly aged 60 and above in China was only 3.8%, starkly contrasting with the United States at 66.7% [36]. Within China's CRD‐afflicted elderly, influenza vaccination rates are as follows: COPD patients at 4.4%, asthma at 9.6%, bronchiectasis at 7.5%, and cancer patients at 5% [37, 38]. The pneumococcal vaccination rate among the elderly in China ranges from 1.8% to 42.1%, whereas, in the United States and the United Kingdom, rates for seniors aged 65 and above soar to 67.5% and 70.6%, respectively. For elderly COPD patients in China, the pneumococcal vaccination rate was only 1.2% [38, 39, 40, 41]. In response to the current low vaccination rates for influenza and pneumococcal vaccines, China has conducted a series of relevant surveys. The results reveal that the predominant reasons behind low vaccination rates include inadequate vaccination awareness, skepticism regarding vaccine efficacy, concerns about the safety and cost, limited recommendations from medical personnel, and poor accessibility to vaccination services [42, 43, 44, 45]. The Application of Influenza and Pneumococcal Vaccines in the Elderly With CRD Vaccine Overview Influenza Vaccine Globally marketed influenza vaccines are categorized into inactivated influenza vaccines, live attenuated influenza vaccines, and recombinant influenza vaccines. Based on their constituents, influenza vaccines are further divided into trivalent and quadrivalent formulations. The trivalent vaccine comprises strains from the A(H1N1) pdm09 subtype, A(H3N2) subtype, and one lineage of the B‐type virus, whereas the quadrivalent formulation includes A (H1N1) pdm09 subtype, A (H3N2) subtype, and the Victoria and Yamagata lineages of B type. In China, approved influenza vaccines include trivalent inactivated influenza vaccine (IIV3), live attenuated influenza vaccine (LAIV3) and quadrivalent inactivated influenza vaccine (IIV4). IIV3 includes both split vaccines and subunit vaccines, suitable for those aged 6 months and older, available in doses of 0.25 mL and 0.5 mL. LAIV3, a lyophilized preparation, is prescribed for individuals aged 3–17 years, with a dosage of 0.2 mL. IIV4 includes both split vaccines and subunit vaccines is applied to those aged 6 months and above, with doses of 0.25 mL and 0.5 mL. High‐dose inactivated influenza vaccines (IIV3‐HD and IIV4‐HD), adjuvanted vaccines, and intradermal vaccines targeting specific populations are also available abroad. Among them, high‐dose inactivated influenza vaccines are sanctioned for individuals aged 65 and above, exhibiting superior protection and eliciting a heightened antibody response compared to standard‐dose vaccines. Individuals eligible for varied vaccine types and brands may opt for any influenza vaccine, with no preferential recommendations. Pneumococcal Vaccine Globally marketed pneumococcal vaccines include pneumococcal polysaccharide vaccine (PPV) and pneumococcal polysaccharide conjugate vaccine (PCV). Developed from streptococcus pneumoniae capsular polysaccharides, these vaccines encompass several frequently occurring serotypes responsible for pneumococcal diseases. Currently, the mainstream PPV globally used is 23‐valent PPV (PPV23), which covers 23 serotypes, namely 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. PPV consists of non‐T cell‐dependent capsular polysaccharide antigens, indicated for individuals aged 2 years and above susceptible to pneumococcal infections. In PCV, capsular polysaccharides covalently bind to proteins, converting the antigen affinity from non‐T‐cell independent to T‐cell dependent. This modification enables infants to generate a robust antibody response and memory after immunization. Currently, there are five types of PPV23 approved for use in China. Globally, the PCVs available on the market primarily include the 7‐valent PCV (PCV7), the 10‐valent PCV (PCV10), the 13‐valent PCV (PCV13), the 15‐valent PCV (PCV15), and the 20‐valent PCV (PCV20), with PCV7 replaced by PCV13. PCV10, authorized by the European Union in 2009, covers serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F. PCV13, developed in 2010 and first approved in the USA, covers serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. The domestically produced PCV13 received Chinese marketing approval in 2020. As of July 2021, PCV15 received FDA approval for market release, aimed at preventing pneumococcal infections and bacterial pneumonia in adults aged 18 and above. PCV15 encompasses PCV13 serotypes alongside two additional variants—22F and 33F—common in invasive pneumococcal disease among the elderly. In June 2021, PCV20 received its first FDA approval for adults aged 18 and above, supplementing the 15 serotypes of PCV15 with five additional serotypes (8, 10A, 11A, 12F, and 15B). On April 27, 2023, PCV20 received FDA approval for expanded use in preventing pneumococcal infections in individuals aged 6 weeks to 17 years. Currently, PCV20 remains under Phase I clinical trials in China. There are currently three types of PCV13 have been approved for use in China, but none has been approved for use in Chinese adults. Moreover, the broad‐spectrum recombinant pneumococcal protein vaccine is also in Phase I clinical trials. Efficacy Analysis Efficacy of Influenza Vaccines Influenza vaccines have proven efficacious in preventing influenza among individuals with COPD, particularly when strains are well‐matched. After vaccination, COPD patients exhibit favorable immunogenicity, manifesting elevated antibody levels. A study in China focusing on COPD patients who received the trivalent influenza vaccine revealed that these patients (average age 64) demonstrated 100% seropositivity for H1N1, H3N2, and B‐type influenza viruses after vaccination. Corresponding seroprotection rates were 96.6%, 93.2%, and 98.9%, with seroconversion rates at 81.8%, 87.5%, and 75.0%, respectively, exhibiting no statistically significant discrepancies among these influenza strains. The geometric mean titers of antibodies for H1N1, H3N2, and B antigens in the micro‐hemagglutination inhibition (HI) test were 18.8, 12.2, and 31.8 at baseline, respectively, and increased to 267.0, 190.3, and 201.1 after vaccination [46]. Patients with COPD experience a significant reduction in acute exacerbations, acute infections, lower risks of related outpatients visits, hospitalization, and mortality after influenza vaccination. A meta‐analysis indicates that influenza vaccination can reduce the frequency of acute exacerbations and related hospitalizations in patients with COPD, particularly among those with an FEV1 < 50% of the predicted value, marking severe to very severe COPD. Additionally, influenza vaccination also notably reduces the annual hospitalization in COPD patients [47]. A multicenter prospective study involving elderly COPD patients demonstrated a reduction of 37.5% in influenza‐related hospitalizations among vaccinated individuals compared to non‐vaccinated ones, with vaccine efficacy estimated at 40.3% [48]. Cohort research in China corroborated influenza vaccination's effectiveness in diminishing COPD and chronic bronchitis patients' acute exacerbation and hospitalization risks [49, 50]. Another study in China, elderly individuals suffering from CRD (such as chronic bronchitis, emphysema, COPD, asthma, and bronchiectasis) were administered either the quadrivalent or trivalent influenza vaccine. A comparative follow‐up was conducted before vaccination and 1 year after vaccination. The results revealed significant reductions in acute exacerbation occurrences, outpatient interventions, hospitalizations, outpatient and hospitalization costs, alongside total medical expenses. No significant differences were discerned between the trivalent and quadrivalent groups [51]. The influenza vaccination shows promising immunogenicity among asthma patients [52]. For asthma patients, influenza vaccination significantly reduces influenza infections and asthma exacerbations [53]. A meta‐analysis indicates that influenza vaccination prevents 59%–78% of asthma exacerbations leading to emergency visits and/or hospitalization [53]. A comparative study included elderly patients hospitalized for influenza (15.8% with asthma) and non‐influenza hospitalizations (7.9% with asthma) to examine the effect of influenza vaccination on both asthmatic and non‐asthmatic patients with confirmed influenza‐related hospitalization, setting unvaccinated, non‐asthmatic patients as the control group. The results demonstrated that vaccination significantly prevented influenza in elderly non‐asthmatic patients and also showed a protective effect in elderly asthmatic patients [54]. Currently, there is limited research on influenza vaccines in patients with bronchiectasis. Chang et al. [55] conducted a review of relevant studies on the effectiveness of influenza vaccination in patients with bronchiectasis and concluded that further research is needed to confirm the efficacy of annual influenza vaccination in this population. Given the current recommendations for influenza vaccination in COPD patients in both domestic and international guidelines, as well as the overlap between COPD and bronchiectasis, annual influenza vaccination remains advisable for bronchiectasis patients. Influenza vaccination for lung cancer patients also elicits higher antibody levels and better immunogenicity. Nakashima et al. [56] conducted a prospective study assessing the immunogenicity of influenza vaccines in cancer patients undergoing chemotherapy, focusing primarily on elderly lung cancer and COPD patients who received a single subcutaneous injection of a trivalent inactivated influenza vaccine. Serum samples were collected before vaccination and 4–6 weeks after vaccination to measure the serum antibody level of hemagglutinin. The results indicated that among lung cancer patients, the seroprotection rates for AH1N1 and H3N2 (titers > 1 : 40 after vaccination) were both 84%, similar to the levels observed in COPD patients. However, the seroprotection rate for the B strain in lung cancer patients was significantly lower than that in COPD patients (64% vs. 92%). Additionally, among cancer patients, those receiving double platinum therapy often exhibit lower serum protection rates compared to those undergoing monotherapy. Overall, lung cancer patients undergoing anticancer chemotherapy exhibited an acceptable immune response to the trivalent influenza vaccine, supporting the recommendation for annual influenza vaccination in lung cancer patients. Research indicated that annual influenza vaccination can also reduce the risk of lung cancer in patients with COPD [57]. A study followed 28,752 COPD patients, of whom 51% (14,630) vaccinated against influenza vaccine, and the remaining 49% unvaccinated. That vaccinated COPD patients had a lower risk of lung cancer, with comparable protection across all genders and age groups (55–64 years, 65–74 years, and ≥ 75 years), regardless of influenza season. Patients who received 2–3 doses and ≥ 4 doses of influenza vaccine had adjusted lung cancer risk ratios of 0.48 and 0.24, respectively, indicating a dose‐dependent protective effect. Some patients with CRDs have used immunomodulators like thymosin α1, which have no contraindications for influenza vaccination. Immunomodulators can regulate one or more immune cells, modulate nonspecific and specific immune functions, enhance the body's defense against pathogens, and improve the clearance of foreign substances in the internal environment. These drugs can also serve as vaccine adjuvants to increase the success rate of influenza vaccination in the elderly and boost patients' immune levels‌ [58]. Immunogenicity of Pneumococcal Vaccines Within 2 years of receiving PCV13 and PPV23 vaccinations, COPD patients demonstrate robust immunogenicity. Patients with COPD exhibit a favorable immunogenic response following a PPV23 dose. Serum antibody titers in COPD patients are comparable to those in age‐matched healthy individuals after PPV23 vaccination. A Japanese study assessed serum IgG antibody concentrations and functional opsonophagocytic antibody (OPA) levels for serotypes 6B, 14, 19F, and 23F in elderly patients with chronic respiratory diseases before and after initial PPV23 vaccination. Post‐vaccination, the geometric mean concentration (GMC) of four specific IgG antibodies and the geometric mean titer (GMT) of OPA antibodies increased significantly by 1.87–2.81 times and 7.43–15.77 times, respectively [59]. A Chinese study involving 89 COPD patients (46.1% aged ≥ 65 years) vaccinated with PPV23 showed that 65.2% (serotype 3) to 94.4% (serotype 2) of COPD patients exhibited a twofold increase in pneumococcal antibody levels post‐vaccination, indicating good immunogenicity of PPV23 in this population [60]. Pneumococcal vaccination may ameliorate clinical manifestations in COPD patients, mitigating the incidence of community‐acquired pneumonia (CAP) and acute COPD exacerbations, thereby reducing associated therapeutic interventions and hospitalizations. Studies indicate that PPV23 vaccination elicits symptom improvement in elderly COPD patients, encompassing eight parameters within the COPD Assessment Test (CAT) score, including cough, chest tightness, and dyspnea [61]. Alfageme et al. [62] conducted research revealing that PPV23 vaccination in COPD patients possessing normal immune function (with an average age of 65.8 years) demonstrated an overall efficacy rate of 24%. Notably, within the subgroup of elderly patients aged 65 and above, the efficacy soared to 76%. Additionally, Walters et al. [63] presented a comprehensive review study in 2017, encompassing 12 randomized controlled trials focused on pneumococcal vaccination in COPD patients (9 of which utilized PPV23). Their findings indicated that pneumococcal vaccination in COPD patients effectively mitigated the risk of acute exacerbation of COPD and community‐acquired pneumonia (CAP). Following PPV23 vaccination, asthma patients exhibited antibody titers comparable to age‐matched healthy controls. Both steroid‐dependent and steroid‐independent asthma cohorts demonstrated elevated serotype‐specific antibody levels 4 weeks post‐PPV23 administration, without statistically significant disparities [64]. Furthermore, asthma patients who received the pneumococcal vaccine experienced a diminished risk of hospitalization attributed to pneumococcal infection [65]. In a Chinese cohort, 28 bronchiectasis patients (with an average age of 53.9 years) were administered PPV23. Over a one‐year follow‐up, these patients exhibited a significantly reduced incidence of recurrent pulmonary infections compared to a control group of 28 unvaccinated bronchiectasis patients (17.85% vs. 45.70%). These findings suggest that PPV23 effectively mitigates the recurrence of lung infections in bronchiectasis patients [66]. For patients diagnosed with lung cancer, the PPV23 has demonstrated efficacy in reducing the incidence of community‐acquired pneumonia (CAP). A targeted study involving lung cancer patients aged 75 years or older revealed that those who received PPV23 vaccination within the first 6 months following diagnosis and initiation of antitumor therapy experienced significant clinical benefits. Compared to unvaccinated controls, the vaccinated cohort exhibited a 26% reduction in CAP incidence. Moreover, the two‐year cumulative CAP hospitalization rate was substantially lower in vaccinated patients (37.1% vs. 55.4%), alongside a notable improvement in overall survival rates (46.6% vs. 26.2% [67]). Safety Assessment Safety of Influenza Vaccine The influenza vaccine exhibits a favorable safety profile, with the most frequently reported adverse reactions being localized (e.g., erythema, swelling, induration, pain, or burning at the injection site) and systemic (e.g., fever, headache, dizziness, lethargy, fatigue, or myalgia). These reactions are typically mild and self‐limiting, resolving spontaneously within 1–2 days, with severe adverse events being exceedingly rare [68]. Notably, a comparative study demonstrated no significant difference in the incidence of post‐vaccination adverse reactions between two high‐risk populations: elderly individuals aged ≥ 65 years and hospitalized patients aged 18–64 years with one or more chronic comorbidities [69]. Current evidence suggests that vaccination does not adversely affect lung function or increase the risk of disease exacerbation in COPD patients during the post‐vaccination period. In a study of 112 elderly patients with stable COPD, no systemic adverse effects were observed following vaccination. Local reactions occurred in only 5.17% of cases, primarily manifesting as erythema and induration at the injection site, all of which resolved either with local heat application or spontaneously within 24–48 h [70]. Furthermore, a multicenter, randomized, double‐blind, placebo‐controlled trial involving 2032 asthma patients (aged 3–64 years) demonstrated no statistically significant difference in acute asthma exacerbation rates between vaccinated and placebo groups within 14 days post‐vaccination [71]. Additional studies have confirmed the safety profile of influenza vaccination in lung cancer patients as well [72]. Safety Profile of Pneumococcal Vaccines Pneumococcal vaccines, including PCV7, PCV13, PCV15, and PPV23, demonstrate a favorable safety profile whether administered alone, concomitantly with other vaccines, or during revaccination. The most frequently reported adverse reactions are localized, such as injection site pain and swelling, while systemic reactions—including fever, myalgia, chills, and arthralgia—are commonly observed in adults and older adults. These symptoms are generally mild and self‐limiting. Rare adverse events have been documented post‐vaccination: febrile seizures occur in fewer than 2 per 10,000 doses following PCV13 administration, while acute severe allergic reactions (anaphylaxis) are exceedingly rare (< 1 per 1,000,000 doses) after PPV23 vaccination [73]. The randomized controlled trial by Alfageme et al. [62], which included 596 COPD patients in Spain (mean age 65.8 years), found that PPV23 vaccination did not cause any local or systemic adverse reactions in these patients. Another study investigating PPV23 vaccination in patients with bronchiectasis or COPD reported a 9.38% incidence of adverse reactions following immunization; all reactions were limited to mild local effects or low‐grade fever that resolved spontaneously, with no cases of severe adverse events such as syncope or anaphylactic shock being observed. These findings demonstrate that PPV23 vaccination is safe for patients with bronchiectasis or COPD [74]. Joint Administration of Influenza Vaccine and Pneumococcal Vaccine in Elderly Patients With CRD The joint administration of influenza and pneumococcal vaccines demonstrates comparable immunogenicity to separate vaccination in elderly [75], with preserved immune responses in patients with respiratory diseases. A 2013 South Korean study involving 224 elderly participants (aged ≥ 65 years) confirmed that coadministration of PPV23 with seasonal influenza vaccine maintained protective antibody levels for both vaccines [76]. This combined vaccination strategy significantly reduces respiratory disease‐related healthcare utilization among elderly patients with chronic conditions, including decreased frequency of outpatient visits, reduced hospitalization rates, shorter hospital stays and effective prevention of influenza and pneumonia. Notably, this approach demonstrates a favorable safety profile with minimal adverse effects [77]. Meta‐analysis of 12 Chinese clinical studies demonstrated that concomitant administration of PPV23 and influenza vaccines in COPD patients yielded significant clinical benefits, including reduction in mean hospitalization duration, decreased annual COPD exacerbation frequency and lower all‐cause mortality risk [78]. Specifically in elderly COPD patients (≥ 60 years), the dual vaccination strategy was associated with a 42% reduction in acute exacerbation frequency, shorter exacerbation duration, decreased hospitalization requirements and significant mortality reduction [79]. Current evidence regarding concomitant administration of influenza and pneumococcal polysaccharide vaccines (PPV23) in specific respiratory populations—including asthma, bronchiectasis, and lung cancer patients—remains limited by the absence of large‐scale clinical trials. However, existing safety data demonstrate that this combined vaccination strategy exhibits an acceptable safety profile in elderly patients [75]. A Chinese observational study involving 2461 vaccine recipients aged ≥ 60 years who received both quadrivalent inactivated influenza vaccine (IIV4) and PPV23 demonstrated favorable safety outcomes, with an overall adverse reaction incidence of 2.07% within the 28‐day post‐vaccination monitoring period. The majority of reported adverse events (1.83%) were classified as Grade 1 reactions (mild severity), while notably absent were any grade 4 adverse reactions or vaccine‐related serious adverse events (SAEs) [80]. Comparative effectiveness analyses between sequential and simultaneous vaccination strategies in elderly patients with chronic comorbidities (including chronic obstructive pulmonary disease [COPD]) revealed that combined immunization conferred equivalent clinical benefits while maintaining comparable safety profiles, without significant increases in adverse event incidence [77, 81]. Guidelines for Influenza and Pneumococcal Vaccination in CRD Population Recommendations for Influenza Vaccination in CRD Population The World Health Organization (WHO) and US Advisory Committee on Immunization Practices (ACIP) specifically recommend annual influenza vaccination for adults aged ≥ 65 years [82, 83]. Similarly, Canada's National Advisory Committee on Immunization (NACI) emphasizes the importance of yearly influenza vaccination for all CRD patients [84, 85]. China's “Technical Guidelines for Seasonal Influenza Vaccination (2023‐2024)” adopt a comprehensive approach, recommending universal influenza vaccination for all individuals ≥ 6 months without contraindications, while prioritizing elderly populations and CRD patients as high‐risk groups requiring special consideration [68]. The 2024 Global Initiative for Chronic Obstructive Lung Disease (2024 GOLD) strongly advises yearly influenza immunization for all COPD patients [86]. This recommendation is echoed in several Chinese consensus documents, including the “Expert Consensus on Immunomodulatory Therapies for Chronic Obstructive Pulmonary Disease”, “Guidelines for the Diagnosis and Management of Chronic Obstructive Pulmonary Disease (2021 Revision)” and “Expert Consensus on the Diagnosis and Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease (2023 Revision)” [14, 87, 88]. Similarly, the 2023 Global Initiative for Asthma (GINA) recommends annual influenza vaccination for patients with moderate‐to‐severe asthma [89, 90], while the British Thoracic Society (BTS) guidelines extend this recommendation to all bronchiectasis patients [91]. For oncology patients, the 2023 National Comprehensive Cancer Network (NCCN) guidelines specifically recommend annual administration of inactivated influenza vaccine for lung cancer patients [92]. Recommendations for Pneumococcal Vaccination in CRD Populations The ACIP recommends that all individuals aged 65 and above should receive either PCV20 alone or a co‐vaccination of PCV15 and PPV23 [93]. The NACI recommends that individuals aged 50 and above who are at high risk for pneumococcal infections, as well as those aged 65 and above, should receive the PCV20 vaccination. If PCV20 is not available, the co‐vaccination of PCV15 and PPV23 is recommended as an alternative [94]. The 2024 GOLD guidelines recommend either a single dose of PCV20 or a sequential administration of PCV15 and PPV23 for COPD patients [86]. Chinese consensus documents, including the “Guidelines for the Diagnosis and Management of Chronic Obstructive Pulmonary Disease (2021 Revision)” and “Expert Consensus on the Diagnosis and Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease (2023 Revision)”, recommend pneumococcal immunization for individuals aged ≥ 60 years or those at high risk of pneumococcal infection [14, 88]. While the 2023 GINA guidelines note insufficient evidence for routine pneumococcal vaccination in all asthma patients, the US Centers for Disease Control and Prevention (CDC) recommends PPV23 vaccination for adults with asthma [90, 95]. The British Thoracic Society (BTS) guidelines advocate pneumococcal vaccination for all bronchiectasis patients, with consideration of PCV13 for those demonstrating inadequate serological response to PPV23 [91]. Additionally, the 2023 NCCN guidelines suggest pneumococcal vaccination at an appropriate clinical timepoint for lung cancer patients [92]. Consensus Recommendations for Vaccination Strategies of Influenza and Pneumococcal Vaccines in the Elderly Population With CRD Consensus Recommendations for Vaccination Strategies of Influenza Vaccine Vaccination Population Elderly individuals with CRD constitute a priority population for influenza vaccination. However, vaccination should be deferred during periods of acute respiratory compromise, including COPD exacerbations, acute asthma attacks, bronchiectasis with acute infection or massive hemoptysis, chemotherapy and radiotherapy for lung cancer patients, and treatment with tumor immune checkpoint inhibitors (it is recommended to vaccinate before the start of antitumor therapy; if antitumor therapy has already begun, it is recommended to vaccinate 2 weeks after the end of antitumor therapy without myelosuppression). Vaccination should be postponed for individuals who are experiencing fever, suffering from other acute illnesses, acute exacerbations of other chronic diseases, or uncontrolled severe chronic conditions. Influenza Vaccination Procedures and Dosage In China, approved influenza vaccines include IIV3, IIV4, and LAIV3 vaccines. For adults aged 18 years and older, either IIV3 or IIV4 is recommended. While this consensus primarily focuses on elderly individuals with CRD, it should be noted that LAIV3 is approved for use in individuals aged 3–17 years and is therefore not recommended in these guidelines. Influenza vaccination can be administered throughout the epidemic season. Protective antibody levels typically develop 2–4 weeks post‐vaccination. To ensure optimal protection, we recommend that all regions initiate vaccination campaigns promptly upon vaccine availability, with completion ideally achieved before the annual local influenza season begins. The standard immunization schedule requires a single 0.5 mL dose of either IIV3 or IIV4 per influenza season, administered via intramuscular injection. For adults, the deltoid muscle of the upper arm is the preferred injection site. Specific vaccination requirements and immunization protocols should adhere to either local vaccination plans or the manufacturer's product instructions. Contraindications for Vaccination Influenza vaccination is contraindicated in individuals with known hypersensitivity to any vaccine component (including excipients, formaldehyde, adjuvants, or antibiotics) or those who have experienced severe allergic reactions to influenza vaccines in the past. Vaccination Precautions (1) Intravenous administration is strictly prohibited; (2) For individuals with bleeding disorders or those on anticoagulant therapy, intramuscular injection may lead to localized bleeding or hematoma—these recipients must be fully informed of potential risks, and vaccination should be performed with extreme caution (preferably shortly after coagulation factor replacement therapy, using a fine‐gauge needle followed by firm pressure on the injection site for ≥ 2 min without massage); (3) Immunocompromised patients or those receiving immunosuppressive treatment may exhibit suboptimal antibody responses; (4) Elderly asthma patients require thorough allergy screening, with cautious administration if significant allergic history is documented; (5) IIV vaccination remains compatible with concurrent influenza antiviral prophylaxis or treatment; (6) Post‐vaccination observation for ≥ 30 min in the designated monitoring area is mandatory for all recipients. Pneumococcal Vaccination Strategies Target Population Elderly individuals with CRD should be prioritized for pneumococcal vaccination. However, vaccination should be deferred in the following circumstances: (1) acute exacerbations of COPD or asthma; (2) acute respiratory infections or active hemoptysis in bronchiectasis patients; (3) ongoing chemotherapy, radiotherapy, or immune checkpoint inhibitor therapy in lung cancer patients (optimal vaccination timing is prior to initiating antitumor therapy; if therapy has already begun, vaccination should be administered ≥ 2 weeks after treatment completion, provided no myelosuppression is present); (4) febrile illness or other acute diseases; (5) acute exacerbations of chronic conditions; or (6) uncontrolled severe chronic diseases. Pneumococcal Vaccination Procedures and Dosage In China, two pneumococcal vaccines are currently approved: PCV13 and PPV23. PCV13 is primarily recommended for infants and preschool children, while this consensus recommends only PPV23 for the elderly with CRD. Individuals with CRD who have never been vaccinated with PPV23 are recommended to receive one dose of PPV23. After the initial vaccination of PPV23, the serotype‐specific IgG concentration and the OPA (opsonophagocytic assay) titers will decrease over time. Therefore, revaccination is necessary (specific vaccine instructions are required). It is recommended that revaccination be conducted at least 5 years after the first vaccination. Due to insufficient safety data regarding the administration of three or more doses of PPV23, further vaccinations after the second dose are not recommended. PPV23 shall be administered by subcutaneous or intramuscular injection via the lateral deltoid muscle of the upper arm with 0.5 mL each time. For specific vaccination requirements, immunization procedures (in particular, whether revaccination is permitted.), please refer to vaccination plans or instructions of different products. Contraindications for Vaccination PPV23 vaccination is strictly contraindicated in individuals with known hypersensitivity to any component of the vaccine formulation. Vaccination Precautions (1) Intravenous injection is strictly prohibited. (2) For individuals with bleeding disorders or those undergoing anticoagulant therapy, intramuscular injection may lead to bleeding or hematoma at the injection site. The potential risks must be clearly communicated to the vaccine recipient, and vaccination should be administered with extreme caution. (3) Patients receiving immunosuppressive therapy or those with immune dysfunction may not achieve the expected serological antibody response. (4) Elderly asthma patients should be thoroughly evaluated for a history of allergies. Vaccination should be administered cautiously if there is a confirmed history of hypersensitivity. (5) The pneumococcal vaccine only provides protection against the serotypes included in the vaccine. It does not prevent invasive diseases caused by non‐vaccine serotypes or other microorganisms, nor does it guarantee complete immunity against pneumococcal diseases in all recipients. (6) After vaccination, the recipient should remain under observation in the designated monitoring area for at least 30 min. Joint‐Vaccination Strategy Elderly patients with CRD eligible for both influenza (IIV) and pneumococcal (PPV23) vaccines may receive them simultaneously during the same visit, with administration at separate anatomical sites recommended to optimize immunogenicity and minimize local reactions. Funding The authors have nothing to report. Conflicts of Interest Qiong Chen is the Editorial Board member of the journal and was excluded from the peer‐review process and all editorial decisions related to the publication of this article. Other authors declare no conflicts of interest.